ArticleObstetrics and gynecology2019
Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma.
Article in Obstetrics and gynecology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Histopathology images-based deep learning prediction of prognosis in primary mucinous ovarian carcinoma.Frontiers in oncology · 2026Article
- Mucinous ovarian neoplasm - outcomes of a rare tumor.Gynecologic oncology reports · 2025Article
- Surgery in Ovarian Cancer-Brazilian Society of Surgical Oncology Consensus.Journal of surgical oncology · 2025Review
- Cellular origins of mucinous ovarian carcinoma.The Journal of pathology · 2025Review
- Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysis.Gynecologic oncology · 2025Article
- Fertility Sparing Medical Management Options in Gynecologic Cancers.Current treatment options in oncology · 2025Review
- The Role ofInternational journal of women's health · 2025Article
- Article
- Case report: Short-course hypofractionated radiation therapy combined with immune checkpoint inhibitors for the treatment of advanced ovarian mucinous cystadenocarcinoma.Frontiers in oncology · 2025Article
- A framework for target discovery in rare cancers.bioRxiv : the preprint server for biology · 2024Article
- Status of and Challenges in Therapy of Mucinous Ovarian Cancer Associated with Pseudomyxoma Peritonei Syndrome: Review of Current Options and Future Treatment Trends.Life (Basel, Switzerland) · 2024Review
- Outcomes after fertility-sparing surgery of early-stage ovarian cancer: A nationwide population-based study.Cancer medicine · 2024Article
- Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas.Cold Spring Harbor perspectives in medicine · 2023Review
- Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance inFrontiers in oncology · 2022Article
- Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.Cancers · 2021Review
- Options for the Treatment of Mucinous Ovarian Carcinoma.Current treatment options in oncology · 2021Review
- Gastrointestinal-type chemotherapy prolongs survival in an atypical primary ovarian mucinous carcinoma: A case report.World journal of clinical cases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo estimate whether gastrointestinal-type chemotherapy was associated with improved survival compared with standard gynecologic regimens for women with ovarian mucinous carcinoma.
methodsWe conducted a retrospective cohort study of patients with ovarian mucinous carcinoma who received postoperative adjuvant chemotherapy at two academic centers. Demographic and clinical information was abstracted from the medical records. Gastrointestinal-type chemotherapy contained 5-fluorouracil, capecitabine, irinotecan, or oxaliplatin. Gynecologic regimens included standard carboplatin or cisplatin. Bevacizumab treatment was allowed in both groups. Summary statistics were used to compare baseline characteristics; Kaplan-Meier product-limit estimator was used to compare survival outcomes.
resultsFifty-two patients received either gastrointestinal-type chemotherapy (n=26; 50%) or a standard gynecologic regimen (n=26; 50%). Three-quarters of tumors were early-stage (I or II), 68% grade 1 or 2 and 88% of patients had no gross residual disease after surgery. Patients receiving gastrointestinal-type chemotherapy were more likely to receive bevacizumab (50% vs 4%; P<.001), but there were no other differences in clinical or demographic characteristics. Unadjusted overall survival analyses showed that gastrointestinal-type chemotherapy was associated with better overall survival (hazard ratio 0.2, 95% CI 0.1-0.8), as were early stage tumors and having no gross residual disease.
conclusionGastrointestinal-type chemotherapy with or without bevacizumab was associated with improved survival and should be considered in patients with ovarian mucinous carcinoma requiring adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.